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Abstract: The ethno-medicinal approach to drug discovery represents one of the most 
important sources of new and safe therapeutic agents to the challenges confronting modern 
medicine and daily life. Many of the traditionally important medicinal plants contain active 
molecules or ones that serve as precursors to biosynthesised secondary metabolites to 
which the biological activity could be attributed. Marrubiin is one such compound and is a 
potential valuable compound which exists in high concentrations in many traditionally 
important Lamiaceae species which have demonstrated excellent pharmacological 
properties with commendably high safety margins. Marrubiin’s attributes include a low 
turnover, high stability and little catabolism, which are core characteristics required for 
therapeutic compounds and nutraceuticals of economic importance. In addition, marrubiin 
is considered a potential substrate for potent active compounds viz; marrubiinic acid, and 
marrubenol. The contribution of marrubiin to drug discovery thus needs to be put into 
prospective due to its ready availability, high potential applications and ease of 
modification. In this short review we highlight the most important chemical and 
pharmacological aspects reported on marrubiin since it was discovered. 
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1. Introduction 
Marrubiin is a widely known diterpenoid lactone that constitutes the bitter principle of the 
horehound and many other medicinal plants of the family Lamiaceae. It is one of the main constituents 
of Marrubium vulgare, Leonotis leonurus and Leonotis nepetifolia [1], which are used in several 
countries to treat different pathologies [2]. According to SciFinder Scholar, there are recently 130 
published articles on marrubiin and these cover the chemical and biological aspects associated with the 
compound. It is a major constituent of many species of the genus Marrubium (Lamiaceae) and 
includes about 97 species found along the Mediterranean and temperate regions of the Eurasian zone. 
Subsequent research revealed that marrubiin is the most active diterpenoid responsible for the 
therapeutic properties observed from the species Leonotis leonurus [3,4], Phlomis bracteosa [5], 
Marrubium deserti de Noe [6], Marrubium vulgare [5,7–19], Marrubium alysson [20] and Marrubium 
thessalum [21,22]. Extensive pharmacological studies have demonstrated that marrubiin displays a 
suite of activities inclusing antinociceptive [12], antioxidant, antigenotoxic [3], cardioprotective [4], 
vasorelaxant [11], gastroprotective [7], antispasmodic [6], immunomodulating [23], antioedematogenic [9], 
analgesic [10,15], and antidiabetic properties [24]. 
2. Occurrence 
Marrubiin was first isolated in Nature from Marrubium vulgare in 1842 and subsequently many 
other plants belonging to the same genus as well as some other members of family Lamiaceae [24] viz; 
Leonotis leonurus [4,5], Phlomis bracteosa [6], Marrubium deserti de Noe [3], M. vulgare [5,17–19], 
M. velatinum [25,26], M. cylleneum [25,26], M. trachyticum [27], M. globosum [28], M. anisodon [29], 
M. sericeum [20], M. supinum [20], M. alysson [20] and M. thassalum [21,22] have been reported to 
contain marrubiin. Only a single report mentioned the isolation of marrubiin from Spiraea brahuica 
belonging to the family Rosaceae [30]. 
3. Physical and Spectroscopic Data [31] 
Synonyms: 6-[2-(3-Furanyl)ethyl]decahydro-6-hydroxy-2a,5a,7-trimethyl-2H-naphtho[1,8-bc]furan-
2-one, 6-[2-(3-furanyl)ethyl]deca-hydro- 6-hydroxy-2a,5a,7-trimethyl-(2aS,5aS,6R,7R,8aR,8bR)-2H-
naphtho[1,8-bc]furan-2-one, 15,16-epoxy-6β,9-dihydroxy-[2aS-(2aα,5aβ,6α,7α,8aα,8bα)]-8βH-labda-
13(16),14-dien-19-oic acid γ-lactone (8CI); marrubiin (6CI); 15,16-epoxy-6β,9-dihydroxy-8βH-labda-
13(16),14-dien-19-oic acid γ-lactone; NSC 36693. Physical properties and assignment of its 1HNMR 
signals are presented in Table 1. 
4. Biosynthesis 
Initially, the common mevalonic acid pathway was proposed for the biosynthesis of terpenoids 
including marrubiin [15,32], however, the results of various 13C-labelled glucose experiments by 
Rohmer were shown to be inconsistent with the expectations based on the mevalonate pathway. 
Consequently, the 1-deoxy-D-xylulose-5-phosphate/2-methyl-D-erythritol-4-phosphate (DOX/MEP) 
pathway has been proposed as the source of this compound in Nature [32–34]. The experimental data 
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showed the production and accumulation of marrubiin in agreement with this newly discovered 
pathway [a non-mevalonate pathway] like in Eubacteria and Gymnospermae [35,36]. 
Table 1. Physical properties and 1H-NMR data of marrubiin [31]. 
Physical properties  Value NMR data [37] 
Molecular weight 332.43 
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1.30dt,  J=14.4, 3.6
1.49qt,  J= 13.6, 13.2, 3.6
1.71*
2.10*
1.44ddd,  J=14.4, 13.6, 3.6
2.22d,  J=4.7
4.73ddd,  J=6.4, 4.7, 1.6
1.67*
2.15ddd,  J=14.0, 6.4, 1.6
2.10*
HA
HB
 1.89ddd,  J=14.6, 10.4, 7.2
1.75ddd,  J=14.6, 10.4 7.2 HB
HA 2.52*
 2.52*
H
6.22dd,  J=1.7, 0.8
H
7.35t,  J=1.7
H 7.22ddt, J=1.7, 1.0, 0.8
28.6
18.2
28.4
43.8
44.9
76.2
31.5
32.3
75.8
39.7
35.1
21.0
125.0
110.7
143.1
138.6
183.8
0.96d J= 6.4 : 16.6
1.28s: 23.0
1.05s : 22.2
* Overlapped signals 
Molecular formula C20 H28 O4 
CAS Registry Number 465-92-9 
Molar volume 288 ± 3.0 cm3/mol(20 °C; 760 Torr) 
Density 1.152±0.06 g/cm3(20 °C; 760 Torr) 
Melting Point ~155–160 °C 
Freely Rotatable Bonds 4 
H Acceptors 4 
H Donors 1 
H Donor/ Acceptor sum 5 
LogP 3.796±0.414 (at 25 °C) 
[α]D: +45.68° (acetone, 24 °C), +35.8 
(CHCl3, 24 °C) 
Pre-furanic (e.g., premarrubiin) and furanic (e.g., marrubiin) labdanoids are widespread in the 
family Lamiaceae [38–40]. There are some ambiguities about the natural origin of the furanic 
labdanoids which possess a C-9 hydroxyl group and a furan ring in the side chain (like marrubiin) 
which are considered by some authors to be the final products in the biosynthetic pathway, while some 
others suggest that they are artefacts which arise from their corresponding prefuran labdanoids during 
or after the extraction or isolation process, by cleavage of the 9,13-epoxide bridge [41–43]. 
According to the recent literature [38], the detection of marrubiin in fresh plant material has been 
reported, together with the isolation of pre-furanic mixed with non-related furanic labdanoids [44–47], 
and these data indicate the existence of marrubiin as a natural compound inside the living organism 
and as an end product of a biosynthetic pathway. The transformation of premarrubiin into marrubiin is 
indicative of the comparative instability of the former compound to the more stable furanic form. 
Generally, under certain conditions the chemical treatment of 9,13–15,16-diepoxylabdane derivatives 
can converted them into the more stable furanic form, and no work has been done to study the effect of 
other substitution patterns in the C11,12 and C14-17 systems, however, many prefuranic structures have 
been isolated without their corresponding furanic forms [44–47]. The relation between premarrubiin 
and marrubiin needs to be investigated in the plant tissues using one of the available advanced 
techniques like high field solid-state NMR. 
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5. Chemical Aspects 
5.1. Synthesis 
Marrubiin was isolated in pure form in 1932 by Mercier and Mercier in a yield of 0.4%. The 
chemistry of marrubiin commenced in the last century and the molecular formula was established by 
Gordin, and its synthesis completed in 1970. 
The synthesis of marrubiin (1) was achieved starting from the keto lactone 5 (Figure 1) which was 
prepared stereoselectively from the known keto ester 2 via 3 and 4 (Figure 1). Compound 5 on reaction 
with Li acetylide followed by reduction gave 6, which gave 7 on treatment with PBr3 in pyridine 
(Figure 2). The bromide 7 was converted into the furanoepoxide 8 (Figure 2) by a reaction with  
3-furanyl lithium followed by epoxidation. The final step, i.e., the conversion of 8 into marrubiin (1) 
was achieved by reduction with lithium in ethylamine [48]. Its stereochemistry had been established by 
chemical transformations and confirmed by X-ray crystallography in 1982 [6,49]. 
Figure 1. Synthesis intermediates of marrubiin (compounds 2–5). 
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Figure 2. Synthesis intermediates of marrubiin (compounds 1, 6–8). 
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5.2. Structure Modification 
There have not been many extensive structure-activity relationship studies made on derivatives of 
marrubiin despite its abundance and high pharmacological activity. Opening of the lactone ring using 
refluxing potassium hydroxide solution afforded the active marrubiinic acid (9, Figure 3) in a yield of 
~70%. Pharmacological studies have shown that marrubiinic acid possesses antinociceptive activity 
against the writhing test, with an LD50 value of 12 µM/kg, being about 11-fold more active than the 
standard drugs (aspirin, paracetamol and morphine) [10]. Marrubenol (10, Figure 3) was obtained from 
marrubiinic acid in a yield of 98% after reduction with lithium aluminium hydride. Marrubenol and 
marrubiin were both found to elicit contractions evoked by high-KCl solutions in aortic segments 
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thereby showing promise as a vasorelaxant. It was found that blocking the free acidic group of 
marrubiinic acid like in the esterified products 11 and 12 (Figure 3) reduced the biological activities, 
which indicates the major role of the free carboxylic group in contributing to the observed  
anti-inflammatory activities. 
Figure 3. Different derivatives of marrubiin (compounds 9–12). 
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On the other hand, during the course of structural elucidations performed in earliest studies, many 
derivatives have been prepared, e.g., compounds 13–17 (Figure 4) without any tests being conducted 
to determine their biological activities [50]. 
Figure 4. Different derivatives of marrubiin (compounds 13–17). 
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6. Pharmacological Aspects of Marrubiin 
6.1. Toxicity Studies 
According to the NIH PubMed website [50] marrubiin doesn’t demonstrate any cytotoxicity against 
66 cancer cell lines, however on the other hand; in vivo experimental studies have documented a LD50 
of 370 mg/kg body weight, for marrubiin [51]. Recent studies have showed a safety limit up to 100 mg/kg 
body weight when injected into mice [9]. 
6.2. Antinociceptive Activity 
De Jesus et al. have reported on the antinociceptive effects of marrubiin and these were found to be 
dose-related. The antinociceptive properties were observed using both the systemic and oral routes and 
its action has sustained over a long period. The high potencies observed in the writhing test and 
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formalin induced pain test suggest that marrubiin is acting by some peripheral mechanism. The 
antinociception induced by marrubiin was not reversed by naloxone when analyzed in the writhing 
test. In the hot-plate test, marrubiin did not increase the latency period of pain induced by the thermal 
stimuli [12]. 
6.3. Cardioprotective Activity 
Although beneficial for cardiomyocyte salvage and to limit myocardial damage and cardiac 
dysfunction, the restoration of blood flow after prolonged ischemia exacerbates myocardial injuries. 
Several deleterious processes that contribute to cardiomyocyte death have been proposed, including 
massive release of reactive oxygen species, calcium overload and hypercontracture development or 
leukocyte infiltration within the damaged myocardium. Chemokines are known to enhance leukocyte 
diapedesis at the inflammatory sites. The diterpenoid marrubiin from Leonotis leonurus extracts was 
found to dampen the hypercoagulable and inflammatory state associated with obesity, therefore 
providing a cardioprotective role. It is clear that marrubiin has been reported to manifest its effects as 
an anti-inflammatory agent through the suppression of NF-κB signalling pathway. Chemokines recruit 
leukocytes to inflammatory sites; an agent that inhibits RANTES possesses cardioprotective action 
through its anti-inflammatory property [11]. The marrubiin extract from L. leonurus inhibited the 
secretion of RANTES, therefore marrubiin has the potential of being a cardioprotective agent as it 
inhibited platelet aggregation, hypercoagulation and the inflammation in vivo. This provided the first 
evidence that inhibition of CCL5/RANTES exerts cardioprotective effects during early myocardial 
reperfusion, through its anti-inflammatory properties. It was found to dampen the hypercoagulable and 
the inflammatory state associated with obesity, thereby providing a cardioprotective role. 
6.4. Gastroprotective (Anti Ulcer) Activity 
The treatment of gastric ulcers includes antacids and antisecretory drugs, mainly antagonists of 
histamine-2 receptors and proton pump inhibitors, which block the secretion of gastric acid. These 
treatments are effective, but may have many adverse effects, such as hypersensitivity, arrhythmia, 
impotence, gynecomastia and hematopoietic disorders. The search for new antiulcer therapies that can 
combine efficacy and lower toxicity like M. vulgare a plant used for treating various diseases, 
including gastric ulcers [10] becomes justifiable and warrants examination. The antiulcer activity of 
the methanolic extract obtained from leaves of M. vulgare and its main compound, the diterpene 
marrubiin, was examined by Paula de Oliveira A. et al. (2011). The gastroprotective activity of 
marrubiin was established through in vivo analysis on assays using different protocols (ulcers induced 
by ethanol/HCl and indomethacin/bethanecol) in mice [7]. In both models, marrubiin (25 mg/kg) 
produced a significant reduction when compared with the control group (p < 0.01). Marrubiin was 
found to contribute to an increase in the defensive mechanisms of the stomach through the production 
of prostaglandin synthesis [10] and the stimulation of the bronchial mucosa [6]. It is reported to have 
antiarrhythmic properties and may induce the cardiac irregularities. The results also demonstrated that 
the gastroprotection by marrubiin is related to the activity of NO and endogenous sulfhydryls, which are 
important gastroprotective factors that have vasodilator effects, thereby inhibiting gastric acid secretion. 
Pre-treatment with L-NAME revealed that the gastroprotective effect of marrubiin is strongly related to 
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NO synthesis, an important endogenous transmitter released by the endothelial cells when mucosa is 
exposed to damaging agents. 
6.5. Anti-Diabetic Activity 
Leonotis leonurus an indigenous South African plant has been reported to be traditionally used to 
cure hypertension [12]. Jao evaluated the aqueous extract for its cardiovascular and hypotensive effects 
in rats and observed that the arterial blood pressures and heart rates of normal, anaesthetized 
spontaneously hypertensive rats were significantly reduced [52]. It was confirmed that the ethanolic 
extract of L. leonurus reduced plasma protein uptake and that marrubiin is responsible for the 
stimulation of insulin secretion in 1NS-1 cells of obese rat model. The anti-diabetic activity of 
marrubiin was studied in vivo using an obese rat model [4], which resulted in an increase in respiratory 
rate and mitochondrial membrane potential under hyperglycemic conditions. Marrubiin was found to 
increase insulin secretion and LDL-cholesterol in this study. In vitro analysis carried out on marrubiin 
confirmed the stimulatory index of INS-1 cells cultured under hyperglycemic conditions, and this was 
significantly increased in cells exposed to them. Furthermore the insulin and glucose transporter-2 
gene expressions were significantly increased by marrubiin [9]. INS-1 cells cultured under 
hyperglycaemic conditions increased chronic insulin secretion by 1.5-fold relative to the 
normoglycaemic control (NGC) cells (p < 0.05). 
6.6. Antispasmodic and Ca2+ Antagonist Potential  
Hussain et al. have demonstrated the antispasmodic potential of marrubiin when administered to 
rabbit jejunum. It caused concentration-dependent relaxation and high K (80 mM)-induced 
contractions, very similar to that caused by verapamil, indicating that marrubiin exhibits spasmolytic 
activity possibly mediated through the Ca2+ channel blocking action [6]. 
6.7. Antioedematogenic Activity 
Marrubiin was evaluated against carregeenan-induced oedema because it is known to be involved in 
the release of different inflammatory agents. Its test is highly sensitive to non-steroidal anti-inflammation 
drugs, and it has long been accepted as a useful phlogistic tool for investigating new anti-inflammatory 
drugs. Marrubiin has significant inhibitory effects on ear oedema. It has been established that kinins 
are pro-inflammatory peptides that mediate a variety of pathophysiological responses. These actions 
occur through the stimulation of two pharmacologically distinct receptor subtypes viz; B1 and B2. The 
fact that there is strong kinin participation in oedematogenic components of the formalin test indicated 
that marrubiin reinforces the hypothesis of the role of kinins in the marrubiin anti-inflammatory 
actions. However, the inhibitory activity of marrubiin on pro-allergic agents such as serotonin and 
histamine was tested with the compound 4880, which has significant inhibitory effects on compound 
4880-induced ear oedema, indicating the possible existence of stabilizing mastocyte membranes, 
analogous to an allergic status. Marrubiin showed a dose-dependent effect when the oedema was 
induced by these agents, suggesting non-specific receptor actions, following the release of serotonin 
and histamine. Various pro-inflammatory agonists were tested against marrubiin in oedema 
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development using microvascular extravasation of Evans blue dye. The results demonstrated that 
marrubiin presents global inhibitory effects on different phlogistic agents, including histamine, and to 
a lesser extent, substance P, participating to a greater or lesser degree in the inflammatory process. 
Antioedematogenic activity of marrubiin was analyzed in a model of microvascular leakage in mice 
ears. The results as reported by Stulzer show that it exhibits significant and dose-related 
antioedematogenic effects. The other phlogistic agonists, such as prostaglandin E2 (PGE2), caused 
inhibition of less than 50%. In addition, marrubiin (100 mg/kg) significantly inhibited the  
OVO-induced allergic oedema in actively sensitized animals (maximal inhibition 67.6 ± 4%) [2,9]. 
6.8. Analgesic Activity 
Success was obtained in reducing the lactone ring of marrubiin which led to the formation of 
marrubiinic acid (9) and two esterified derivatives exhibited significant analgesic effect using the 
writhing test in mice. Marrubiinic acid showed higher activity and excellent yield, and its analgesic 
effect was confirmed in other experimental models of pain, suggesting its possible use as a new and 
useful analgesic agent [10]. 
6.9. Anticoagulant and Antiplatelet Activities 
Anticoagulant and antiplatelet activities of marrubiin have also been detected. According to 
Mnonopi et al. marrubiin was found to significantly prolong activated partial thromboplastin time 
(APTT) with fibrin and D-dimer formation being drastically decreased TNF-α and RANTES secretion 
were also reduced by the extract and marrubiin when measured in the obese rat model relative to the 
controls. Calcium mobilization and TXB2 synthesis were also suppressed [4]. Several diterpenoids 
from M. cylleneum and M. velutinum were tested for their cytotoxic effects against various cancer cell 
lines and their immunomodulating potential in human peripheral blood mononuclear cells were 
standardized. The results showed a differential cytotoxicity of compounds as well as their ability to 
improve selected lymphocyte functions [22]. 
6.10. Vasorelaxant Potential 
The result of Khan et al. revealed that marrubiin present among other constituents from Phlomis 
bracteosa exhibited vasodilator action via a combination of endothelium-independent Ca2+ antagonism 
and endothelium dependent NÃ¹-nitro-L-arginine methyl ester-sensitive nitric oxide-modulating 
mechanisms [53]. The crude extracts of the aerial parts of M. vulgare showed appreciable potently in 
vitro inhibition of KCl-induced contraction of rat aorta [11] thereby indicating vasorelaxant properties 
in this medicinal plant extract. 
7. Conclusions 
Marrubiin exists in high concentrations in many traditionally important Lamiaceae species and has 
demonstrated excellent pharmacological properties with high safety margins in different inflammation 
models. The low turnover, high stability and little catabolism further indicate its importance and it 
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comparatively, little has been done concerning its chemical modifications and the examination of the 
associated bioassay data merits continued chemical investigation. 
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